United Advisor Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.87M Buy
1,561
+231
+17% +$236K 0.2% 132
2026
Q1
$1.22M Sell
1,330
-157
-11% -$159K 0.15% 165
2025
Q4
$1.6M Buy
1,487
+294
+25% +$281K 0.2% 120
2025
Q3
$911K Buy
1,193
+387
+48% +$288K 0.12% 174
2025
Q2
$628K Buy
806
+261
+48% +$203K 0.11% 188
2025
Q1
$450K Buy
545
+133
+32% +$111K 0.09% 202
2024
Q4
$318K Sell
412
-188
-31% -$156K 0.06% 286
2024
Q3
$532K Buy
+600
New +$539K 0.12% 181

Other funds holding LLY

United Advisor Group's LLY Position: Q2 2026 in Review

United Advisor Group increased its Eli Lilly (LLY) stake by 17% in Q2 2026, buying an estimated $236K and bringing the position to 1,561 shares worth $1.87M. The position accounts for 0.2% of the portfolio, ranked #132.

United Advisor Group first reported a position in LLY in Q3 2024 and has held it in 8 quarters since. 4,630 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • United Advisor Group held 1,561 shares of Eli Lilly worth $1.87M as of Q2 2026.
  • United Advisor Group bought 231 Eli Lilly shares in Q2 2026, an estimated $236K.
  • Eli Lilly made up 0.2% of United Advisor Group's portfolio in Q2 2026, its #132 holding.
  • United Advisor Group first reported a position in Eli Lilly in Q3 2024 and has held it in 8 quarters since.
  • 4,630 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on United Advisor Group's 13F filing for Q2 2026, filed 29 Jul 2026.